Efficacy of OPTIMEALTH FOOD on Gut health

Submission date 15/07/2024	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 05/08/2024	Overall study status Completed	 Statistical analysis plan Results
Last Edited 26/02/2025	Condition category Digestive System	Individual participant data[X] Record updated in last year

Plain English summary of protocol

Background and study aims

The gut microbiota plays an important role in regulating human health and diseases. A growing body of knowledge supports the involvement of Gut microbiota dysbiosis in diseases such as diabetes, obesity, inflammatory bowel disease IBD and constipation. This study evaluates the efficacy of a postbiotic metabolite complex OPTIMEALTH FOOD P developed by Innovation Labo, Tokyo. OPTIMEALTH® FOOD P was developed by studying the microbiota and health of healthy centenarians who have a particular microbiota profile. Innovation Labo discovered that the metabolites produced by the microbiote activate gene expression to inhibit and regulate inflammation and modulate the gut microbiome. The present study will evaluate the effect of OPTIMEALTH FOOD P on constipation. To evaluate this, parameters such as changes in defecation frequency, stool consistency, constipation-related symptom scores, changes in stool short-chain fatty acid (SCFA) content, gut microbiota composition and changes in levels of oxidative biomarkers in blood will be evaluated.

Who can participate?

Non-smoker adult subjects aged between 21 to 65 years old (inclusive) who have general symptoms of constipation and meet ROME III criteria for functional constipation

What does the study involve?

Participants will be randomly assigned to a once-daily OPTIMEALTH FOOD P supplement or a placebo/dummy supplement for 4 weeks.

What are the possible benefits and risks of participating: Possible benefits are a reduction in constipation. No risk is expected.

Where is the study run from? INNOVATION LABO Sciences Co., Ltd (Japan)

When is the study starting and how long is it expected to run for? January 2023 to February 2024

Who is funding the study? INNOVATION LABO Sciences Co., Ltd (Japan) Who is the main contact? Dr Yuki Ikeda, development@innovationlabo.com (Japan)

Contact information

Type(s) Scientific

Contact name Dr Yuki Ikeda

ORCID ID http://orcid.org/0000-0001-6067-4574

Contact details Shintomi HJ bldg 5F 1-12-7 Shintomi Tokyo Japan 104-0041 +81 335525335 development@innovationlabo.com

Type(s) Principal Investigator

Contact name Dr Taro Hirata

Contact details 14-5 Kusunokichō, Nishi-ku, Yokohama-shi, Kanagawa-ken Yokohama Japan 220-0003 +81 335525335 coordinate@medica-labs.jp

Type(s)

Public

Contact name

Mrs Aki Honda

Contact details Shintomi HJ bldg 5F 1-12-7 Shintomi Tokyo Japan 104-0041 +81 335525335 tokyo@innovationlabo.com

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers Nil known

Study information

Scientific Title

A prospective, randomized, double-blind, two-arm, parallel, placebo-controlled, clinical study to evaluate the efficacy of OPTIMEALTH® FOOD P supplementation on constipation symptoms, SCFAS content, and gut microbiota composition in healthy participants suffering from constipation

Study objectives

OPTIMEALTH FOOD P is more efficient than an placebo in improving constipation symptoms, increasing SCFAs content and improving gut microbiota composition

Ethics approval required

Ethics approval required

Ethics approval(s)

1. Approved 10/10/2023, Japanese Society of Anti-Aging Nutrition (Ginza, Chuo-ku, Tokyo, 104-0061, Japan; +81 3 3552 5277; coordinator@jaan.jp), ref: ILOS24614-P782

2. Approved 17/10/2024, Swiss Association of Anti-aging Nutrition (Löwenstrasse 11, Zürich, 8001, Switzerland; +41 79 811 47 83; rfaber.saan@gmail.com), ref: 2023/10-GFR105

Study design

Interventional double-blind placebo-controlled single-center randomized clinical trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Home

Study type(s)

Quality of life

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Improvement of constipation symptoms

Interventions

This study investigates 4 weeks of daily supplementation with Optimealth Food (300 mg/day, 150mg x 2 capsules) or a placebo (dextrin, 300 mg/day, 150mg x 2 capsules) taken orally at breakfast. Block randomization was used to allocate participants to each group.

Block randomization is used to divide potential patients into m blocks of size 2n, randomize each block such that n patients are allocated to A and n to B then choose the blocks randomly. This method ensures equal treatment allocation within each block if the complete block is used.

Intervention Type

Supplement

Primary outcome measure

Defecation frequency self-assessment measured using a daily chart at baseline and week 4

Secondary outcome measures

The following secondary outcome measures are assessed at baseline and week 4:

- 1. Stool consistency by self-assessment measured using the Bristol stool chart
- 2. Constipation-related symptom scores measured using a self-assessment questionnaire
- 3. Stool short-chain fatty acid (SCFA) content measured using gas chromatography
- 4. Gut microbiota composition measured using quantitative PCR

5. Oxidative biomarker levels in blood measured using a ferric reducing antioxidant power (FRAP) assay

Overall study start date

07/01/2023

Completion date 05/02/2024

Eligibility

Key inclusion criteria

1. Healthy adult subjects between 21 and 65 years (inclusive) of age

2. General symptoms of constipation and meet ROME III criteria for functional constipation

3. BMI between 18.5 and 29.9 Kg/m^2

4. Females of child-bearing potential must agree to use an approved form of birth control and to have a negative pregnancy test result at the screening visit. Female subjects of non-childbearing potential must be amenorrheic for at least 1 year or had a hysterectomy and/or bilateral oophorectomy.

5. Willing to give written informed consent and be willing to comply with trial protocol

6. The ability to understand the risks/benefits of the protocol

7. Available for the duration of the study period (6 weeks)

Participant type(s)

Patient

Age group Adult

Adult

Lower age limit

21 Years

Upper age limit 65 Years

Sex Both

Target number of participants

60

Total final enrolment

60

Key exclusion criteria

- 1. Constipation due to organic or neurological lesions
- 2. A history of pathological bowel diseases like IBD or colon cancer
- 3. Abnormal liver or renal function

4. Taken any prebiotic, probiotic or laxative supplements within 8 weeks from the start of the study period

- 5. Receiving any antibiotic, antiinflammatory or immunosuppressive drug within the past 4 weeks
- 6. Known allergies to soy milk or any other test product ingredients
- 7. Alcoholics and or drug abusers
- 8. Pregnant or lactating females
- 9. A history of anxiety or depression or recent intake of psychotropic drugs

10. Any other condition which the Principal Investigator thinks may jeopardize the study outcome

Date of first enrolment 07/11/2023

Date of final enrolment

25/12/2023

Locations

Countries of recruitment Japan

Switzerland

Study participating centre Medica Tokyo Laboratories

14-5 Kusunokichō, Nishi-ku Yokohama-shi Kanagawa-ken Yokohama Japan 220-0003

Study participating centre Swiss Biome Institute Hegenheimermattweg 167A Allschwil Switzerland 4123

Sponsor information

Organisation INNOVATION LABO SCIENCES Co., Ltd

Sponsor details Shintomi HJ bldg 5F, 1-12-7 Shintomi Tokyo Japan 104-0041 Chuo-ku +81 (0)3 35525335 technologies@innovationlabo.com

Sponsor type Industry

Website https://www.innovationlabo.com

Funder(s)

Funder type Industry Funder Name INNOVATION LABO Sciences Co., Ltd

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date 31/10/2024

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Yuki Ikeda, development@innovationlabo.com. Anonymised IPD will be available upon publication of results and for a period of 2 years. Consent from participants was required and obtained.

IPD sharing plan summary

Available on request